Effect of captopril, losartan, and bradykinin on early steps of insulin action

Diabetes

Volumn 46, Issue 12, 1997, Pages 1950-1957

  Carvalho, Carla R O ^a   Thirone, Ana Claudia P ^a   Gontijo, Jose A R ^a   Velloso, Licio A ^a   Saad, Mario J A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; GROWTH REGULATION; INSULIN METABOLISM; INSULIN RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0030728725     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.12.1950     Document Type: Article

References (62)

1. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17:448-454, 1987
2. Henriksen EJ, Jacob S: Effects of captopril transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272, 1995
3. Donnelly R: Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 20 (Suppl. 11):S38-S44, 1992
4. Berne C: Metabolic effects of ACE inhibitors. J Intern Med 229 (Suppl. 2):119-125, 1991
5. Pacheco CA, Ramirez LC, Rios JM, Raskin P: Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 89:811-812, 1990
6. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
7. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E: Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 17:170-178, 1991
8. Paolisso G, Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F: Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40:972-977, 1991
9. Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ: Glucose transport activity in insulin-resistant rat muscle: effect of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 45 (Suppl. 1):S125-S128, 1996
10. Herings RMC, Boer A, Stricker BHCh, Leufkens HGM, Porsius A: Hypoglycaemia associated with use of inhibitors of angiotensin-converting enzyme. Lancet 345:1195-1198, 1995
11. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1-5, 1994
12. Ebina Y, Araki E, Taira M, Shimada F, Mori M, Craik CS, Siddle K, Pierce SB, Roth RA, Rutter WJ: Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci USA 84:704-708, 1987
13. Chou CK, Dull TJ, Russel DS, Gherzi R, Lewohl D, ullrich A, Rosen OM: Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262:1842-1847, 1987
14. White MF, Maron R, Kahn CR: Insulin rapidly stimulates tyrosine phosphorylation of a Mr 185,000 protein in intact cells. Nature 318:183-186, 1985
15. Maegawa H, Olefsky JM, Thies S, Boyd D, Ullrich A, McClain MA: Insulin receptor with defective tyrosine kinase inhibits normal receptor function at the level of substrate phosphorylation. J Biol Chem 261:16597-16603, 1988
16. Momomura K, Tobe K, Seyama Y, Takaku F, Akanuma Y, Kasuga M: Insulin-induced tyrosine phosphorylation in intact rat adipocytes. Biochem Biophys Res Commun 155:1181-1186, 1987
17. Sun XJ, Rothenberg PL, Kahn CR, Backer JM, Araki E, Wilden P, Cahill DA, Goldstein BJ, White MF: Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77, 1991
18. Lamphere L, Carpenter CL, Sheng ZF, Kallen RG,Lienhard GE: Activation of PI 3-kinase in 3T3-L1 adipocytes by association with insulin receptor substrate-1. Am J Physiol 266:E486-E494, 1994
19. Backer JM, Myers MG Jr, Schoelson SE, Chin DJ, Sun XJ, Miralpeix M, Hu P, Margolis B, Skolnik EY, Schlessinger J, White MF: The phosphatidylinositol 3-kinase is activated by association with 1RS-1 during insulin stimulation. EMBO J 11:3469-3479, 1992
20. Folli F, Saad MJA, Backer JM, Kahn CR: Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin resistance and insulin-deficient diabetes mellitus. J Clin Invest 92:1787-1794, 1993
21. Saad MJA, Hartmann LGC, Carvalho DS, Galoro CAO, Brenelli SL, Carvalho CRO: Effect of glucagon on insulin receptor substrate-1 (IRS-1) phosphorylation and association with phosphatidylinositol 3-kinase (PI 3-kinase). FEBS Lett 370:131-134, 1995
22. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinoditol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204, 1995
23. Carvalho CRO, Brenelli SL, Silva AC, Nunes ALB, Velloso LA, Saad MJA: Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology 137:151-159, 1996
24. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR: Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90:1839-1849, 1992
25. Lavan BE, Kuhne MR, Garner CW, Anderson D, Rudijk M, Pawson T, Lienhard GE: The association of insulin-elicited phosphotyrosine proteins with Src homology domains. J Biol Chem 267:11631-11636, 1992
26. Kelly KL, Ruderman NB: Insulin-stimulated phosphatidylinositol 3-kinase: association with a 185-kDa tyrosine-phosphorylated protein (IRS-1) and localization in a low density membrane vesicle. J Biol Chem 268:4391-4398, 1993
27. Giorgetti S, Balloti R, Kowalski-Chawel A, Tartare S, VanObberghen E: The insulin and insulin-like growth factor-1 receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem 268:7358-7364, 1993
28. Hara K, Yonezawa K, Sakaue H, Ando A, Koton K, Kitamura T, Kitamura Y, Ueda H, Stephens L, Jackson TR, Hawkins PT, Dhand R, Clark AE, Holman GD, Waterfield MD, Kasuga M: Phosphoinositide 3-kinase activity is required for insulin-stimulated glucose transport but not for ras activation in CHO cells. Proc Natl Acad Sci USA 91:7415-7419, 1994
29. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR: Phosphatidylinositol 3 kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 14:4902-4911, 1994
30. Clarke JF, Young PW, Yonezawa K, Kasuga M, Holman GD: Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300:631-635, 1994
31. Yeh JI, Gulve EA, Rameh L, Birbaum MJ: The effects of wortmannin on rat skeletal muscle: dissociation of signaling pathways for insulin- and contraction-activated hexose transport. J Biol Chem 270:2107-2111, 1995
32. Sanches-Margalet V, Golfine ID, Vlahos CJ, Sung CK: Role of phosphatidylinositol 3-kinase in insulin receptor signaling: studies with inhibitor LY 294002. Biochem Biophys Res Commun 204:446-452, 1994
33. Welsh GI, Foustone EJ, Young SW, Tavaré JM, Proud CG: Wortmannin inhibits the effects of insulin and serum on the activities of glycogen synthase kinase-3 and mitogen-activated protein kinase. Biochem J 303:15-21, 1994
34. Yamauchi K, Milarski KL, Saltiel AR, Pessin JE: Protein tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Biochemistry 92:664-668, 1995
35. Laemmlli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
36. Towbin H, Staehlin J, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354, 1979
37. Bonora E, Moghetti R Zancanaro C, Gigolini M, Querena M, Cacciatoni V, Corgnati A, Muggeo M: Estimation of in vivo insulin action in man: comparison of insulin tolerance test with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68:374-378, 1989
38. Stephens JM, Pilch PF: The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter. Endocr Rev 16:529-546, 1995
39. Quon MJ, Butte AJ, Zamowski MJ, Sesti G, Cushman SW, Taylor SI: Insulin receptor substrate-1 mediates the stimulatory effect of insulin on GLUT4 translocation in transfected rat adipose cells. J Biol Chem 169:27920-27924, 1995
40. Haruta T, Morris AJ, Rose DW, Nelson JG, Mueckler M, Olefsky JM: Insulin stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. J Biol Chem 270:27991-27994, 1995
41. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL: The phosphatidylinositol 3-kinase serina kinase phosphorylates IRS-1: stimulation by insulin and inhibition by wortmannin. J Biol Chem 269:20648-20652, 1994
42. Soubrier F, Alhenc-Gelas F, Hubeert C, Allegrini J, John M, Tregear G, Corvol P: Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85:9386-9390, 1988
43. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490-12495, 1996
44. Saad MJA, Velloso LA, Carvalho CRO: Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 310:741-744, 1995
45. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Kurumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N: Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 23:450-455, 1994
46. Gulati K, Lall SB: Angiotensin II receptor subtypes characterization and pathophysiological implications. Indian J Exp Biol 34:91-97, 1996
47. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539-24542, 1993
48. Dzau VJ, Sasamura H, Hein L: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl 11:S13-S18, 1993
49. Bottari SP, de Gasparo M, Steckelings UM, Levens NR: Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications. Front Neuroendocrinol 14:123-171, 1993
50. Timmermans PB, Smith RD: The diversified pharmacology of angiotensin II receptor blockade. Blood Press Suppl 2:53-61, 1996
51. Yang HYT, Erdös EG, Levin Y: A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta 214:374-376, 1970
52. Rett K, Wicklmayr M, Dietze GJ, Haring HU: Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 45 (Suppl. 1):S66-S69, 1996
53. Isami S, Kishikawa E, Araki E, Uehara M, Kaneko K, Shirotani T, Todaka M, Ura S, Motoyoshi S, Matsumoto K, Miyamura N, Shichiri M: Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 39:412-420, 1996
54. Uehara M, Kishikawa H, Isami S, Kisanuki K, Ohkubo Y, Mitamura N, Miyata T, Yano T, Shichiri M. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37:300-307, 1994
55. Torlone E, Rambotti AM, Periello G, Botta G, Santeusanio F, Brunetti P, Bolli GB: ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 34:119-125, 1991
56. Hirooka Y, Imaizuma T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A: Captopril improved impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 20:175-180, 1992
57. Kodoma J, Katayama S, Tanaka K, Kawazu S, Ishii J: Effect of captopril on glucose concentration: possible role of augmented postprandial forearm blood flow. Diabetes Care 13:1109-1111, 1990
58. Häring HU, Tippmer S, Kellerer M, Mosthaf L, Kroder G, Bossenmaier B, Berti L: Potential mechanisms of a cross-talk between bradykinin and insulin receptor. Diabetes 45 (Suppl. 1):S115-S119, 1996
59. Rett K, Wicklmayr M, Dietze GJ: Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril (Letter). N Engl J Med 319:1609, 1988
60. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P: Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 89:811-813, 1990
61. Fernere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J: Captopril and insulin sensitivity (Letter). Ann Intern Med 102:134, 1985
62. Winocour P, Waldek S, Anderson DC: Captopril and blood glucose (Letter). Lancet 23:461, 1986